People: Cepheid (CPHD.O)

Summary

Name	Age	Since	Current Position
John Bishop	68	2013	Chairman of the Board, Chief Executive Officer
Andrew Miller	52	2012	Chief Financial Officer, Executive Vice President
Humberto Reyes	67	2008	Chief Operating Officer, Executive Vice President
David Persing	57	2005	Executive Vice President, Chief Medical and Technology Officer, Director
Joseph Smith		2013	Executive Vice President - Business Development, General Counsel
Kerry Flom	61	2013	Executive Vice President, Chief Regulatory Officer
Philippe Jacon	53	2013	Executive Vice President - International Commercial Operations
Warren Kocmond	49	2013	Executive Vice President - Global Operations
Cristina Kepner	67	2013	Lead Independent Director
Thomas Brown	65	2006	Independent Director
Robert Easton	68	2002	Independent Director
Thomas Gutshall	75	2013	Independent Director
Dean Morton	80	1997	Independent Director
Hollings Renton	66	2000	Independent Director
Glenn Steele	68	2011	Independent Director
Jacquie Ross			IR Contact Officer

» Insider Trading

Biographies

Name	Description
John Bishop	Mr. John L. Bishop is Chairman of the Board, Chief Executive Officer of Cepheid. Mr. Bishop joined the company as Chief Executive Officer and as a director in April 2002 and became the company Chairman of the Board in February 2013. Mr. Bishop served as President and a director of Vysis, Inc., a genomic disease management company that was acquired by Abbott Laboratories, from 1993 to 2002 and as Chief Executive Officer from 1996 to 2002. From 1991 until 1993, Mr. Bishop was Chairman and Chief Executive Officer of MicroProbe Corporation, a biotechnology company, and, from 1987 until 1991, of Source Scientific Systems, a biomedical instrument manufacturing company. From 1984 to 1986, Mr. Bishop was President and Chief Operating Officer of Gen-Probe, Inc. From 1968 to 1984, Mr. Bishop held various management positions with American Hospital Supply Company and its affiliates, including a three-year assignment in Japan as an Executive Vice President and Chief Executive Officer of International Reagents Corp., a joint venture between American Hospital Supply Company and Green Cross Corporation. Mr. Bishop currently serves as a director of Conceptus, Inc. In addition, he is a member of the AdvaMed Dx Board.
Andrew Miller	Mr. Andrew D. Miller is Chief Financial Officer, Executive Vice President of Cepheid. Mr. Miller first joined the company in April 2008 as Senior Vice President, Chief Financial Officer, and became the company Executive Vice President, Chief Financial Officer in January 2012. Prior to joining the company, Mr. Miller was Vice President of Finance and Chief Accounting Officer for Autodesk, an enterprise software company, from March 2005 to April 2008 and Vice President of Finance and Corporate Controller from May 2003 to March 2005. At Autodesk, he was responsible for global accounting and compliance operations. Before joining Autodesk, from 2000 to 2003, Mr. Miller was Senior Vice President and Chief Financial Officer for MarketFirst Software, Inc., a provider of enterprise marketing automation software. Prior to MarketFirst, Mr. Miller served as Vice President of Worldwide Finance for Cadence Design Systems, Vice President of Finance and Corporate Controller for Adaptive Broadband Corporation, and held senior financial roles for Silicon Graphics, Inc. Mr. Miller was a Certified Public Accountant.
Humberto Reyes	Mr. Humberto Reyes is Chief Operating Officer, Executive Vice President of Cepheid. Mr. Reyes joined the company as Senior Vice President of Operations in November 2004, became the company Executive Vice President, Operations in November 2006 and became the company Executive Vice President, Chief Operating Officer in May 2008. Prior to joining the company, Mr. Reyes was an Operations Consultant with Brownsboro Group, LLC. from 2003 to 2004. Prior to joining Brownsboro, Mr. Reyes was a Senior Operations Consultant for EXPERTech Associates, consulting in medical devices and biotech industries from 2001 to 2003. Prior to that, he was Head of Operations for OXIS Health Products Inc., which developed, manufactured and marketed products for oxidative research and wellness programs from 1997 to 2001. He is an experienced operations executive with more than 25 years of progressive management experience in the diagnostic and related industries. Mr. Reyes’ work experience also includes Vice President, Operations, Dade Diagnostics at Baxter; Vice President/General Manager, Chromatography Division, Varian and Associates; and Sr. Vice President, Operations, Microgenics Corporation.
David Persing	Dr. David H. Persing, M.D., Ph.D., is Executive Vice President, Chief Medical and Technology Officer, Director of Cepheid. Dr. Persing first joined the company as a director in May 2004, and became the company Executive Vice President and Chief Medical and Technology Officer in August 2005. From 1999 to 2005, Dr. Persing was Senior Vice President and Chief Scientific Officer at Corixa Corporation, a Seattle-based biotechnology company, until its acquisition by GlaxoSmithKline. From 1990 to 1999, he was a member of the Clinical and Research Faculty of the Mayo Clinic in Rochester, Minnesota where he conducted research on hepatitis viruses, tick-borne infections and molecular diagnostics. In 1992, he founded and directed the Molecular Microbiology Laboratory at Mayo Clinic. Dr. Persing is a member of the advisory board of Catalysis, a non-profit foundation based in Emeryville, CA. Dr. Persing served as a director of Monogram Biosciences, Inc. from December 2000 until August 2009, when it was acquired by Laboratory Corporation of America Holdings. He has authored over 240 peer-reviewed articles and served as Editor in Chief for four textbooks on Molecular Diagnostics, the most recent of which was published by ASM press in October 2010.
Joseph Smith	Mr. Joseph H. Smith is Executive Vice President - Business Development, General Counsel of Cepheid. Mr. Smith joined the company in June 2003 as Vice President, General Counsel and has served as the company Senior Vice President of Business Development and General Counsel from April 2004 until December 2012 and was promoted to Executive Vice President of Business Development and General Counsel in January 2013. He has been Secretary since March 2004. From 1989 to 2002, Mr. Smith was Vice President of Intellectual Property at Applied Biosystems (now Life Technologies Corporation) and its predecessors, a biotechnology research equipment company, and from 2002 to 2003 was its Senior Vice President for Business Development. Prior to Applied Biosystems, Mr. Smith was a partner in the law firm of Wiseman, Jones, and Smith; and prior to that he was a member of the Technical Legal Department of Hewlett-Packard.
Kerry Flom	Dr. Kerry J. Flom, Ph. D., is Executive Vice President, Chief Regulatory Officer of Cepheid., since January 2013. He was the company Senior Vice President, Clinical Affairs & Regulatory Submissions from January 2010 until December 2012, after having joined the company in May 2004 as Vice President, Clinical Affairs & Regulatory Submissions. Prior to joining the company, Dr. Flom was Senior Director, Clinical Affairs and Regulatory Submission for Abbott Molecular Diagnostics from 2001 to 2004. Prior to Abbott, Dr Flom directed the clinical affairs departments at Vysis, Inc., Baxter Health Corporation – Cardiovascular Group (presently Edwards Lifesciences), and Oncor, Inc. Before joining Oncor, Dr. Flom held clinical and R&D positions at Boehringer Mannheim Corporation (presently Roche Diagnostics), Behring Diagnostics, and Corning Corporation.
Philippe Jacon	Mr. Philippe Jacon is Executive Vice President - International Commercial Operations of Cepheid., since January 2013. He is responsible for the company international growth strategy, encompassing both commercial sales and the HBDC program. Prior to joining the company, Mr. Jacon was CEO of the Foundation for Innovative New Diagnostics (FIND) and Director General ad interim of the European Diagnostic Manufacturers Association (EDMA). Before joining EDMA in March of 2011, Mr. Jacon held a number of positions of increasing responsibility with Becton Dickinson (BD), most recently as Worldwide President of BD Diagnostics, Diagnostic Systems and Worldwide President of BD Diagnostics, Microbiology Systems. Other roles during his 23 years at BD included Vice President and General Manager for BD Medical, Diabetes Care in Europe and Vice President and General Manager for BD Medical, Pharmaceutical Systems in the United States.
Warren Kocmond	Mr. Warren C. Kocmond, Jr., has been appointed as Executive Vice President - Global Operations of Cepheid effective May 6, 2013. Mr. Kocmond most recently served as Vice President of Global Operations at Lam Research Corporation, a water fabrication equipment and services supplier, from February 2012 until April 2013, where he was responsible for globally dispersed operations including a multi-billion dollar supply chain. From August 2009 until October 2011, Mr. Kocmond served as Executive Vice President of Global Operations and Quality at Verigy, Ltd., now a wholly owned subsidiary of Advantest Corp., a provider of semiconductor automatic test equipment. Mr. Kocmond served as the Chief Operating Officer of Electroglas, Inc., a supplier of semiconductor manufacturing equipment and software, from May 2008 until February 2009 when he was promoted to Chief Executive Officer and served in that role until July 2009. Prior to that, from May 2007 until May 2008, Mr. Kocmond served as the Senior Vice President of Global Operations for Affymetrix, Inc., a manufacturer of DNA microarrays. Mr. Kocmond holds a B.S. in mechanical engineering from the University of Nevada, Reno, and an M.S. in systems management from the University of Southern California.
Cristina Kepner	Ms. Cristina H. Kepner is Lead Independent Director of Cepheid. Ms. Kepner joined the company as a director in May 1998. Since February 2013, she has served as the company Lead Independent Director. She was with Invemed from 1978 to 2000, where she served in a variety of capacities. Prior to retiring from Invemed in December 2000, Ms. Kepner served as Executive Vice President and Corporate Finance Director. Ms. Kepner served as a director of Monogram Biosciences, Inc. from May 1996 until August 2009, when it was acquired by Laboratory Corporation of America Holdings, and as a director of Quipp, Inc. from January 1995, including Chairman of the board of directors from April 2004, until June 2008, when it was acquired by Illinois Tool Works Inc.
Thomas Brown	Mr. Thomas D. Brown is Independent Director of Cepheid., since February 7, 2006. Mr. Brown joined Abbott Laboratories in 1974 as a sales representative in the company’s Diagnostics Division (ADD). From 1977 until his retirement in 2002, he held numerous sales, marketing and general management positions within ADD. From February 1998 until his retirement at Abbott Laboratories in July 2002, he held the position of Senior Vice President, President Diagnostic Division. In 1993, he was elected Corporate Vice President, Worldwide Diagnostic Commercial Operations. In 1992, he was named Divisional Vice President, Commercial Operations. In 1987, he was named Divisional Vice President and General Manager, Western Hemisphere Commercial Operations.
Robert Easton	Mr. Robert J. Easton is Independent Director of Cepheid. Mr. Easton is co-founder and co-chairman of Bionest, a strategic consulting firm specializing in evaluation and planning for pharmaceutical and medical device and diagnostic companies. Mr. Easton was director and Vice President of Apex Bioventures, which he co-founded, from 2007 to 2009. He was a director of CollaGenex Pharmaceuticals, Inc. from 1994 until its sale in 2008. From 2000 to 2006, he was co-founder and Chairman of Easton Associates, LLC, and before that, from 1996 to 2000, he was a Managing Director of IBM Healthcare Consulting. Mr. Easton spent 12 years with Union Carbide and Union Carbide Europe in multiple functional roles, including marketing and engineering management roles in the Clinical Diagnostics business unit.
Thomas Gutshall	Mr. Thomas L. Gutshall is Independent Director of Cepheid. Mr. Gutshall is a co-founder of Cepheid. He served as Chairman of the Board from August 1996 until February 2013. From August 1996 until April 2002, he also served as the company Chief Executive Officer. From January 1995 to August 1996, he was President and Chief Operating Officer of CV Therapeutics, and served on its board of directors for fourteen years. From 1989 to 1994, he was Executive Vice President at Syntex Corporation and a member of the Pharmaceutical Executive Committee. His responsibilities while at Syntex included managing Syva Company, Syntex Agribusiness, Pharmaceutical and Chemical Operations and Services, Syntex Pharmaceutical Intl. Ltd. and Environmental Health and Safety.
Dean Morton	Mr. Dean O. Morton is Independent Director of Cepheid., since July 1997. Morton retired in 1992 as Executive Vice President, Chief Operating Officer and a director of Hewlett-Packard Company, where he started in 1960. In addition, he served as a director of BEA Systems from March 1996 to April 2008, when it was acquired by Oracle Corporation, Pharsight Corporation from April 2000 to November 2008, when it was acquired by Tripos International, and Alza Corporation from 1987 to June 2001, when it was acquired by Johnson & Johnson. From 1993 to 2002, Mr. Morton served on the board of Kaiser Foundation Health Plan and Hospitals and was a member of the Executive Committee. Prior to that, he was a member of the board of the Stanford University Hospital for ten years. Mr. Morton was a member of the board of the David and Lucile Packard Foundation from 1989 to 2002 and served as the Chair of the Finance Committee, and was a public member of the board of commissioners of the Joint Commission on Accreditation of Healthcare Organizations from 1993 to 1997.
Hollings Renton	Mr. Hollings C. Renton is Independent Director of Cepheid., since March 2000. Mr. Renton retired from Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, in March 2008, where he had served as a director beginning in April 1992, President and Chief Executive Officer beginning in March 1993 and Chairman of the Board beginning in June 2003. From 1991 to 1993, he served as President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, following its acquisition of Cetus Corporation. Prior to the acquisition, he served as President of Cetus Corporation from 1990 to 1991 and as Chief Operating Officer from 1987 to 1990. Mr. Renton also serves as a member of the Boards of Directors of Affymax, Inc., Rigel Pharmaceuticals and Portola Pharmaceuticals.
Glenn Steele	Mr. Glenn D. Steele, Jr., M.D., Ph.D., is Independent Director of Cepheid., since April 26, 2011. Dr. Steele has served as President and Chief Executive Officer of Geisinger Health System, a physician-led health care system serving multiple regions of Pennsylvania, since March 2001. Prior to that, he was at the University of Chicago where he served as the Richard T. Crane Professor in the Department of Surgery, Vice President for Medical Affairs, and Dean of the Biological Sciences Division and of the Pritzker School of Medicine. Dr. Steele also serves on the boards of Bucknell University, Temple University School of Medicine, Premier Inc. as Chairman, Weis Markets Inc., Wellcare Health Plans Inc. and the American Hospital Association Committee of Research.
Jacquie Ross

Basic Compensation

Name	Fiscal Year Total
John Bishop	3,776,600
Andrew Miller	3,076,620
Humberto Reyes	1,399,190
David Persing	1,456,930
Joseph Smith	961,089
Kerry Flom	--
Philippe Jacon	--
Warren Kocmond	--
Cristina Kepner	--
Thomas Brown	--
Robert Easton	--
Thomas Gutshall	142,198
Dean Morton	--
Hollings Renton	--
Glenn Steele	--
Jacquie Ross	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
John Bishop	1,072,088	6,801,494
Andrew Miller	79,499	1,862,740
Humberto Reyes	313,957	3,610,660
David Persing	411,750	2,745,200
Joseph Smith	310,000	1,141,451
Kerry Flom	0	0
Philippe Jacon	0	0
Warren Kocmond	0	0
Cristina Kepner	0	0
Thomas Brown	0	0
Robert Easton	0	0
Thomas Gutshall	250,000	1,396,250
Dean Morton	0	0
Hollings Renton	0	0
Glenn Steele	0	0
Jacquie Ross	0	0

Insider Trading

Name	Shares Traded	Price
MILLER ANDREW D	22,468	$38.51
MILLER ANDREW D	10,000	$8.43
GUTSHALL THOMAS L	3,000	$37.90
FLOM KERRY J	3,750	$8.43
FLOM KERRY J	2,500	$20.47
FLOM KERRY J	6,832	$39.76
EASTON ROBERT J	342	$39.96
KEPNER CRISTINA H	670	$39.96
BROWN THOMAS D	464	$39.96
STEELE GLENN D JR	360	$39.96
REYES HUMBERTO V	339	$0.00
BISHOP JOHN L III	1,250	$0.00
PERSING DAVID H	339	$0.00
MILLER ANDREW D	1,250	$0.00
REYES HUMBERTO V	128	$38.66
SMITH JOSEPH H	164	$38.66
BISHOP JOHN L III	653	$38.66
PERSING DAVID H	128	$38.66
MILLER ANDREW D	470	$38.66
SMITH JOSEPH H	313	$0.00
STEELE GLENN D JR	700	$0.00
PERSING DAVID H	302	$0.00
MILLER ANDREW D	250	$0.00
FLOM KERRY J	77	$38.42
MILLER ANDREW D	94	$38.42

» Full list on Insider Trading

People: Cepheid (CPHD.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: